Baird analyst David Rescott raised the firm’s price target on ResMed (RMD) to $283 from $280 and keeps an Outperform rating on the shares. The firm said they’re increasingly confident in likely upside, as market growth remains stable, the company maintains and in some cases gains share, and benefits from expanding AirSense 11 roll-out.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: